+

WO1995022995A1 - Compositions de contraste radiologique contenant des derives de la cellulose - Google Patents

Compositions de contraste radiologique contenant des derives de la cellulose Download PDF

Info

Publication number
WO1995022995A1
WO1995022995A1 PCT/GB1995/000386 GB9500386W WO9522995A1 WO 1995022995 A1 WO1995022995 A1 WO 1995022995A1 GB 9500386 W GB9500386 W GB 9500386W WO 9522995 A1 WO9522995 A1 WO 9522995A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
halo
ray contrast
composition
Prior art date
Application number
PCT/GB1995/000386
Other languages
English (en)
Inventor
Carl R. Illig
John Toner
Edward James Baker
Robert Lee
Tom Caulfield
Brent D. Douty
Kurt Josef
Edward R. Bacon
Kimberly Estep
Saul Daum
Eugene R. Cooper
Original Assignee
Nycomed Imaging A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/201,731 external-priority patent/US5422114A/en
Priority claimed from US08/206,552 external-priority patent/US5443814A/en
Priority claimed from US08/217,138 external-priority patent/US5385721A/en
Priority claimed from US07/216,988 external-priority patent/US5385720A/en
Priority claimed from US08/222,787 external-priority patent/US5466435A/en
Priority claimed from US08/227,423 external-priority patent/US5368837A/en
Priority claimed from US08/227,415 external-priority patent/US5525327A/en
Priority claimed from US08/227,422 external-priority patent/US5543132A/en
Priority claimed from US08/229,048 external-priority patent/US5385722A/en
Priority claimed from US08/246,888 external-priority patent/US5607660A/en
Priority to JP7522205A priority Critical patent/JPH09509424A/ja
Priority to MX9603611A priority patent/MX9603611A/es
Application filed by Nycomed Imaging A/S filed Critical Nycomed Imaging A/S
Priority to CN95192256A priority patent/CN1146159A/zh
Priority to AU18163/95A priority patent/AU1816395A/en
Priority to EP95909853A priority patent/EP0746339A1/fr
Publication of WO1995022995A1 publication Critical patent/WO1995022995A1/fr
Priority to FI963299A priority patent/FI963299A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0495—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound intended for oral administration

Definitions

  • This invention relates to x-ray contrast
  • compositions containing contrast agents and cellulose derivatives and methods for their use in diagnostic radiology of the gastrointestinal tract.
  • CT computed tomography
  • GI tract Roentgenographic examination of the GI tract is indicated for conditions of digestive disorders, changes in bowel habit, abdominal pain, GI bleeding and the like.
  • administration of a radiopaque contrast medium Prior to radiological examination, administration of a radiopaque contrast medium is necessary to permit adequate delineation of the respective lumen or mucosal surface from surrounding soft tissues. Accordingly, a contrast medium is administered orally to visualize the mouth, pharynx, esophagus, stomach, duodenum and
  • the contrast medium is administered rectally for examination of the distal small intestine and the colon.
  • the most widely used contrast agent for the visualization of the GI tract is barium sulfate
  • barium sulfate has certain disadvantages. In the presence of intestinal fluids it lacks homogeneity and adheres poorly to mucus membranes which can result in poor X-ray images. In the colon, when administered as an enema, it flocculates and forms irregular clumps with fecal matter.
  • Iodinated organic compounds have also been used as GI contrast agents since the iodine atom is an effective X-ray absorber. They have the most versatility and are utilized in the widest variety of procedures . They are very absorptive of X-rays with which the iodine
  • the desiderata for an ideal GI contrast agent include: good toxicological profile; the ability to fill the entire bowel/lumen and evenly coat the gut mucosa so that the presence of the bowel is detectable when the lumen is not distended; palatability and nonirritation to the intestinal mucosa; and passage through the GI tract without producing artifacts or stimulating
  • U.S. Patent No. 4,069,306 discloses an x-ray contrast preparation which is said to adhere to the walls of body cavities.
  • the preparation comprises a finely divided water-insoluble inorganic x-ray contrast agent and minute particles of a hydrophilic polymer which is insoluble in water but is water-swellable.
  • the body cavity is supplied with such preparation suspended in water.
  • the x-ray contrast agent is present in admixture with and/or enclosed in and/or adhered to said minute polymer particles.
  • composition for barium opacification of the digestive tract comprising colloidal barium sulfate and a polyacrylamide in an aqueous vehicle.
  • polyacrylamide forms a viscous solution at low
  • U.S. Patent No. 5,019,370 discloses a biodegradable radiographic contrast medium comprising biodegradable polymeric spheres which carry a radiographically opaque element, such as iodine, bromine, samarium and erbium.
  • the contrast medium is provided either in a dry or liquid state and may be administered intravenously, orally and intra-arterially.
  • Japanese Patent Application No. 55-127322 discloses x-ray contrast compositions containing barium sulfate and a polymeric substance selected from carboxy ⁇ ethyl cellulose salts, propylene glycol alginate, cellulose sulfate polyacrylate, pectin and tragacanth gum.
  • the polymeric substance is used to increase the viscosity of the compositions.
  • compositions for coating the gastrointestinal tract of mammals to form an effective radiopaque coating thereon by which diagnostic examination of the GI tract may be accomplished.
  • a thin coating is formed on the inner surface of the GI tract effected by ingesting, prior to visualization by an x-ray emitting device, a cellulose derivative, which has incorporated therein an x-ray contrast agent, capable of coating the GI tract.
  • both the x-ray contrast agent and the cellulose derivative must be nontoxic; must not contain leachable or digestible components that would
  • composition comprising: an x-ray contrast agent in a pharmaceutically acceptable vehicle comprising a cellulose derivative.
  • a method for x-ray diagnostic imaging of the GI tract which comprises orally or rectally administering to the patient an effective contrast producing amount of the above-described x-ray contrast compostion.
  • the x-ray contrast agent of the present invention is selected from:
  • Z is H, halo, C 1 -C 20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups;
  • R 1 and R 2 are independently H, C 1 -C 25 alkyl
  • cycloalkyl acetyl or halo-lower-alkyl, wherein said C 1 -C 25 alkyl, cycloalkyl and halo-lower-alkyl are
  • n 1-4;
  • y is 1-4;
  • x is 1 or 2;
  • R is a substituted or unsubstituted alkyl group containing from 2 to 8 carbon atoms, wherein said substituents are selected from the group consisting of C 1 -C 6 alkyl, hydroxy and alkoxy;
  • n 1 to 5; ( 3 ) compounds of the formula
  • Z is H, halo, C 1 -C 2o alkyl, cycloalkyl -lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups;
  • R 1 , R 2 , R 3 and R 4 are independently lower-alkyl, optionally substituted with halo;
  • x 1-3
  • y is 1-4;
  • n 1-5;
  • n 1-15;
  • p 1-10;
  • Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower-alkyl;
  • R is methyl , ethyl , n-propyl , C 4 -C 25 alkyl ,
  • R 1 , R 2 , R 3 and R 4 are independently H, lower-alkyl, optionally substxtuted with halo;
  • n 2-5;
  • n 2-5;
  • p 1-10;
  • Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower-alkyl;
  • Z is H, halo, C 1 -C 20 alkyl, cycloalkyl, lower
  • R is C 1 -C 25 alkyl, cycloalkyl, or halo-lower-alkyl; each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy
  • R 1 , R 2 , R 3 and R 4 are independently H or lower-alkyl, optionally substituted with halo;
  • x is 1-4;
  • n 1-4;
  • n 1-15;
  • p 1-20;
  • Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower-alkyl;
  • X is or -SO 2 -
  • Z is H, halo, C 3 -C 20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups;
  • R is C 1 -C 25 alkyl, cycloalkyl, aryl or halo-lower- alkyl, each of which may be optionally substituted with lower-alkoxy, hydroxy, carboxy or lower-alkoxy-carbonyl, lower-alkenyl, lower-alkynyl, lower-alkylene or lower-alkoxy-carbonyloxy;
  • n 1-5;
  • y is 0-4;
  • w is 1-4;
  • Z is H, halo, C 1 -C 20 alkyl , cycloalkyl , lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups ;
  • R is methyl , ethyl , propyl , C 9 -C 25 alkyl ,
  • R 1 , R 2 , R 3 and R 4 are independently lower-alkyl, optionally substituted with halo;
  • x is 1-4;
  • n 1-5;
  • n 1-15;
  • p 1-10;
  • Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower-alkyl;
  • iodinated polymeric, water-insoluble beads having a particle size of from about 0.01 to about 1000 ⁇ wherein said iodinated polymeric beads comprise a polymer containing repeating units of the formula (I)
  • A is a repeating organic unit in the backbone chain of the polymer.
  • X is an organic moiety containing an iodinated aromatic group and a hydrophilic group, said moiety having an iodine content within the range of from about 40 to about 80 weight percent based on the molecular weight of X;
  • halogen means fluorine, chlorine, bromine or iodine.
  • cycloalkyl means fluorine, chlorine, bromine or iodine.
  • carbocyclic rings having from three to eight ring carbon atoms including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl which may be substituted on any ring carbon atom thereof by one or more lower-alkyl groups, lower-alkoxy groups or halogens.
  • lower-alkyl and lower- alkoxy mean monovalent aliphatic radicals, including branched chain radicals, of from one to ten carbon atoms.
  • the, lower-alkyl moiety of such groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n-hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, 1,1,3,3-tetramethylpentyl, 1,1-dimethyloctyl and the like.
  • lower-alkenyl and lower-alkynyl means monovalent, unsaturated radicals including branched chain radicals of from three to ten carbon atoms and thus include 1-ethenyl, 1-(2-propenyl), 1-(2-butenyl), 1-(1-methyl-2-propenyl), 1-(4-methyl-2-pentenyl), 4,4,6-trimethyl-2-heptenyl, 1-ethynyl, 1-(2-propynyl), 1-(2-butynyl), 1-(1-methyl-2-propynyl), 1-(4-methyl-2-pentynyl) and the like.
  • alkylene means divalent saturated radicals, including branched chain radicals of from two to ten carbon atoms having their free valences on different carbon atoms and thus includes 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1-methyl-1, 2-ethylene, 1,8-octylene and the like.
  • aryl means an aromatic hydrocarbon radical having six to ten carbon atoms.
  • the preferred aryl groups are phenyl, substituted phenyl and naphthyl substituted by from one to three, the same or different members of the group consisting of lower-alkyl, halogen, hydroxy-lower-alkyl, alkoxy-lower-alkyl and hydroxy.
  • the x-ray contrast compounds of types (1) - (7) above can comprise one, two, three or four iodine atoms per molecule; preferred species contain at least two, and more preferably, at least three iodine atoms per molecule.
  • Solid x-ray contrast agents in particulate form useful in the practice of the present invention can be prepared by techniques known in the art. The solid agents are comminuted to the desired size using
  • an effective average particle size of less than about 100 ⁇ provides for good distribution and coating in the GI tract.
  • particle size refers to a number average particle size as measured by conventional techniques, such as sedimentation field flow fractionation and disk centrifugation.
  • An effective average particle size of less than about 100 ⁇ means that at least about 90% of the particles have a weight average particle size of less than about 100 ⁇ as measured by art recognized techniques.
  • the cellulose derivatives utilized in the present invention include methylcellulose,
  • carboxymethylcellulose sodium carboxymethylcellulose, hydroxyethyl methylcellulose, hydroxypropyl
  • methylcellulose and macrocrystalline cellulose; having an average particle size of from 0.01 to 100 ⁇ , more preferably of from 0.05 to 10 ⁇ , and most preferably of 0.1 to 1 ⁇ m.
  • the contrast agent and the cellulose derivative are formulated for administration using physiologically acceptable carriers or excipients in a manner within the skill of the art.
  • the contrast agent and the cellulose derivative with the addition of pharmaceutically acceptable aids (such as surfactants and emulsifiers) and excipients are suspended or partially dissolved in an aqueous medium resulting in a dispersion, solution, suspension or emulsion.
  • a method for diagnostic imaging of the GI tract for use in medical procedures in accordance with this, invention comprises orally or rectally administering to the mammalian patient in need of x-ray examination, an effective contrast producing amount of a composition of the present invention. After administration, at least a portion of the GI tract containing the administered composition is exposed to x-rays to produce an x-ray image pattern corresponding to the presence of the contrast agent, then the x-ray image is visualized and interpreted using techniques known in the art.
  • Preferred contrast agents of type (2) have the formula:
  • R is a secondary alkyl group containing from 4 to 8 carbon atoms.
  • the most preferred contrast agent of type (2) is the sec-octyl ether of 2,4,6-triiodophenol having the formula:
  • the contrast agents of type (2) are slightly soluble in water, having a partition coefficient equal or greater than 10. This degree of solubility allows the formation of stable formulations ii: the form of emulsions and suspensions when the formulations contain the requisite excipients.
  • the term ' stable means that there is no separation of the ingredients contained in the compositions after oral or rectal administration thereof and during radiological examination of the GI tract.
  • the slight solubility of the contrast agents in aqueous media permits diffusion of the contrast agents into the intestinal mucosa and secretions thereby forming a coating on the intestines. On the other hand, due to their slight solubility, the absorption of the contrast agent into the intestinal walls is minimal which reduces the possibility of toxic side effects.
  • compositions of type (8) defined above are non-radioactive and exist as a
  • the crystalline phase differs from an amorphous or non- crystalline phase which results from solvent
  • the organic substance can be present in one or more suitable crystalline phases.
  • the invention can be practiced with a wide variety of crystalline, non-radioactive x-ray contrast agents.
  • the x-ray contrast agent must be poorly soluble and dispersible in at least one liquid medium.
  • “poorly soluble” it is meant that the agent has a solubility in the liquid dispersion medium, e.g., water, of less than about 10 mg/ml, and preferably of less than about 1 mg/ml.
  • the x-ray contrast agent can be an iodinated compound.
  • the iodinated compound can be aromatic or nonaromatic. Aromatic compounds are preferred.
  • the iodinated compound can comprise, one, two, three or more iodine atoms per molecule. Preferred species contain at least two, and more preferably, at least three iodine atoms per molecule.
  • the iodinated compounds selected can contain substituents that do not impart solubility to the compound, such as, for example, alkylureido, alkoxyacylamido, hydroxyacetamido, butyrolactamido, succinimido, trifluoroacetamido, carboxy, carboxamido, hydroxy, alkoxy, acylamino, and the like substituents.
  • a preferred class of contrast agents includes various esters and amides of iodinated aromatic acids.
  • the esters preferably are alkyl or substituted alkyl esters.
  • the amides can be primary or secondary amides, preferably alkyl or substituted alkyl amides.
  • the contrast agent can be an ester or amide of a substituted triiodobenzoic acid such as an acyl, carbamyl, and/or acylmethyl substituted triiodobenzoic acid.
  • Illustrative representative examples of iodinated aromatic acids include, but are not limited to,
  • diatrizoic acid metrizoic acid, iothalamic acid, trimesic acid, urokonic acid, ioxaglic acid (hexabrix), ioxitalamic acid, tetraiodoterephthalic acid,
  • trimers (sometimes referred to as bis compounds), trimers
  • Classes of preferred contrast agents have the following structural formulae:
  • R can be OR 1 , NR 2 R 3 , alkylene, -CO.OR 1 or -O-alkylene-CO.OR 1 wherein R 1 is alkyl, and R 2 and R 3 are independently H or alkyl.
  • Each alkyl group can independently contain from 1-20, preferably 1-8, and more preferably, 1-4 carbon atoms.
  • the alkylene group preferably contains from 1 to 4 carbon atoms such as methylene, ethylene, propylene and the like.
  • diatrizoic acid i.e., ethyl (3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)acetate, also known as ethyl diatrizoxyacetate; and ethyl 2-(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)butyrate, also known as ethyl 2-diatrizoxybutyrate.
  • ethyl (3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)acetate also known as ethyl diatrizoxyacetate
  • ethyl 2-(3,5-bis(acetylamino)-2,4,6-triiodobenzoyloxy)butyrate also known as ethyl 2-diatrizoxybutyrate.
  • the invention can be practiced in conjunction with the water insoluble iodinated carbonate esters described in PCT/EP90/00053.
  • x-ray contrast agents are known compounds and/or can be prepared by techniques known in the art.
  • water-insoluble esters and terminal amides of acids such as the above-described iodinated aromatic acids can be prepared by conventional alkylation or amidation techniques known in the art.
  • the above-noted acids and other acids which can be used as starting materials are commercially available and/or can be prepared by techniques known in the art.
  • the particles useful in the compositions of type (8) defined above include a surface modifier.
  • Surface modifiers useful herein physically adhere to the surface of the x-ray contrast agent but do not chemically react with the agent or itself .
  • Individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.
  • Suitable surface modifiers can be selected from known organic and
  • inorganic pharmaceutical excipients such as various polymers, low-molecular weight oligomers, natural' products and surfactants.
  • Preferred surface modifiers include nonionic and anionic surfactants.
  • surface modxfxers include 0d"e gelatin, casein, lecithin (phosphatides), gum acacxa, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g.. macrogol ethers such as cetomacrogol 1000,
  • polyoxyethylene castor oil derivatives polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium,
  • hydroxypropylmethycellulose phthalate noncrystalline cellulose
  • magnesium aluminum silicate triethanolamine
  • polyvinyl alcohol polyvinylpyrrolidone
  • PVP polyvinylpyrrolidone
  • Particularly preferred surface modifiers include polyvinylpyrrolidone, tyloxapol, poloxamers such as
  • Pluronic F68 and F108 which are block copolymers of ethylene oxide and propylene oxide, and poloxamines such as Tetronic 908 (also known as Poloxamine 908), which is a tetrafunctional block copolymer derived from
  • Carbowax 3350 and 934 which are polyethylene glycols available from Union Carbide.
  • Surface modifiers which have been found to be particularly useful include
  • a particularly preferred class of surface modifiers includes water-soluble or water-dispersible compounds having the formula
  • L' is a chemical bond, -O-, -S-, -NH-, -CONH- or -SO 2 NH-;
  • R is a hydrophobic substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted aryl group;
  • each of R 1 and R 2 independently is hydrogen or an alkyl group having from 1 to 4 carbon atoms;
  • each of a and b independently is 0 or an integer from 1 to 3, provided that the sum of a and b is not greater than 3;
  • each of x and y independently is an integer from 3 to 7.
  • R contains from 6 to 36 carbon atoms
  • R is an n-alkyl group containing from 6 to 18 carbon atoms
  • each of R 1 and R 2 independently is a methyl, ethyl, propyl or butyl group and a is 0 and b is 0.
  • This class of surface modifiers is described in U.K. Patent Application No. 9104957.7 filed March 8, 1991 and can be prepared by reacting an appropriate dicarboxylic acid ester with an appropriate monosaccharide amine, preferably in the absence of a solvent, at a reaction temperature from 140 to 200°C.
  • the surface modifiers are commercially available and/or can be prepared by techniques known in the art. Two or more surface modifiers can be used in combination.
  • the particles useful in the compositions of type (8) defined above can be prepared in accordance with the wet grinding process described in U.S. Patent No.
  • the process comprises dispersing a poorly soluble x-ray contrast agent in a liquid dispersion medium and wet-grinding the agent in the presence of grinding media to reduce the particle size of the contrast agent to an effective average particle size of from about 0.05 ⁇ to about 100 ⁇ , preferably of from about 0.05 ⁇ to about 5 ⁇ and most preferably from about 0.1 ⁇ to about 1 ⁇ .
  • the particles can be reduced in size in the presence of a surface modifier.
  • the particles can be contacted with a surface modifier after attrition.
  • particle size refers to a number average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation.
  • an effective average particle size of from about 0.05 ⁇ to about 100 ⁇ is meant that at least 90% of the particles have a weight average
  • particle size of from about 0.05 ⁇ to about 100 ⁇ when measured by the above-noted techniques.
  • the particle size range allows sufficient number of particles' distribution in the film forming composition when the GI tract is coated therewith, yet insures against
  • polymers of the invention is represented by structural formula I above.
  • the backbone chain of the iodinated polymer can represent:
  • condensation polymer such as a polyester, polyamide, polyurethane, polycarbonate, polyepoxide, polyether, a phenol-formaldehyde polymer and equivalent condensation polymers
  • addition polymerizable monomers containing a polymerizable unsaturated double bond e.g., vinyl monomers, including such addition polymers as poly(vinyl alcohol),
  • a naturally occurring polymer for example, a polysaccharide containing repeating glucose units such as starch, glycogen, cellulose, cellulosic derivatives, and equivalent naturally occuring polymers.
  • repeating units A of formula I are preferably identical to repeating units A of formula I
  • a repeating unit having an appended hydroxyl group such as the repeating unit of poly (vinyl alcohol), the repeating epoxy unit of a polyepoxide, the repeating unit of a hydroxylated acrylic polymer such as poly (hydroxyethylacylate), or the repeating glucose unit of a naturally occurring polysaccharide.
  • the appended hydroxyl group can serve either as a crosslinking site or as a reaction site for precursor compounds of the organic moiety X in formula I .
  • precursor compounds can be chemically linked to the repeating units of the polymer backbone chain through a condensation reaction with the appended hydroxy group.
  • the organic moiety X of formula I above represents an iodine-containing organic fragment comprising an iodinated aromatic group and one or more hydrophilic groups.
  • the iodinated aromatic group have multiple iodine substituents bonded directly to the aromatic carbon ring atoms.
  • Especially preferred among these iodinated aromatic groups are aromatic groups containing three, preferably four, carbon ring atoms substituted by iodine.
  • a preferred iodinated aromatic group is an iodinated phenyl ring, although napthyl rings and nitrogen-containing heterocyclic rings containing 5 to 7 ring atoms can also be used.
  • An especially preferred iodinated aromatic group is a phenyl ring bearing iodine substituents on a 4 of the carbon ring atoms.
  • hydrophilic group (s) of X are typically present as a substituent (s) bonded directly, or indirectly through a chemical linking group, to one or more of the carbon ring atoms of the iodinated aromatic group.
  • linking groups include short chain aliphatic groups, e.g., alkylene groups, amido groups and
  • hydrophilic groups can be selected from a variety of such groups including carboxyl groups; sulfo groups; amino groups; salts thereof such as carboxylate salts, sulfonate salts, ammonium salts; polyols such as glucose groups; and equivalent hydrophilic groups.
  • the precursors from which the organic moiety X of formula I is derived contains a reactive group which forms a chemical linking group with the repeating unit of the polymer backbone chain.
  • the reactive group contained on the precursor of X is a group reactive with the hydroxy group.
  • the reactive group can be a carboxyl group which condenses with the appended hydroxy group of the backbone chain to form an ester group linking an
  • iodinated aromatic moiety of the polymer backbone A variety of other reactive groups which react with a hydroxy group to form such chemical linking groups as ethers, amides, thioesters, carbonates, carbamates, sulfides, and equivalents, can also be used.
  • a partial listing of precursors for the moiety X of formula I includes, for example, 3-(3-amino-2,4,6 -triiodophenyl)-2-ethylpropionic acid; 3-(3-hydroxy-2,4,6-triiodophenyl)-2-ethylpropionic acid; sodium 3-(3-butyrylamino-2,4,6-triiodophenyl)-2-ethylacrylate; 3,5-diiodo-4-pyridone-N-acetic acid; 3-acetamido-2,4,6-criiodobenzoic acid; tetraiodophthalic anhydride; and the like Tetraiodophthalic anhydride can be
  • A is as defined in formula I above;
  • X is as defined in formula I above;
  • L represents one of the above-described linking groups, e.g. ester, ether, amide, thioester, carbonate, carbamate, sulfide and the like; and each of R 1 to R 6 which may be the same or different, represents hydrogen, an iodine-containing substituent, or a hydrophilic group-containing substituent, with the proviso that the iodine content of X is from about 40 to 80 percent
  • Preferred iodinated polymers are crosslinked. This can enhance the water-insolubility and resistance to swell properties of the polymer.
  • Crosslinking can be effected by incorporation of suitable crosslinking sites either on the polymer backbone chain or on the moiety X or both.
  • a hydroxyl group appended to the backbone chain of one polymer can react with the carboxyl gru ⁇ p attached to the sidechain X of another polymer, thereby crosslinking the two polymers through an ester linkage.
  • polymeric contrast agents of the invention contain both hydrophilic and hydrophobic groups.
  • X also contains one or more
  • hydrophilic groups This combination of hydrophobic and hydrophilic groups is believed important to provide the proper polymer surface and electrical characteristics which, in turn, provide proper polymer compatibility with body organs and tissues.
  • the iodinated polymers can be prepared by any of a variety of conventional polymerization and chemical reaction techniques.
  • a preferred reaction sequence is to chemically react precursor compounds for the side-chain group X with a preformed polymer containing appended groups serving as suitable reaction sites, e.g., hydroxyl groups.
  • the preformed polymer can be prepared by addition or condensation polymerization, depending on the polymer; or it can be obtained from naturally occurring sources in the case of naturally occurring polymers; e.g., polysaccharides.
  • precursor compounds for the moiety X can be reacted with the reaction site on the polymer backbone by a variety of well-known reaction procedures, depending on the nature of the linking group L in formula II above which is formed in this reaction.
  • the reaction of these precursor compounds is carried out under emulsifying conditions so that the resultant polymers are obtained in finely-divided particulate form.
  • Crosslinking can be carried out during or following attachment of the moiety X of the polymer backbone.
  • the polymer can be subjected to grinding or milling
  • the polymers may already have an appropriate particle size so that additional milling or grinding may be unnecessary.
  • a useful particle size for these polymer particles is within the range of from about 0.01 to 1000 microns , preferably 0.1 to 100 microns.
  • the preferred barium salt (the contrast agent of type (10) mentioned above) is barium sulfate which is a white, radiopaque, crystalline powder that is
  • compositions of the present invention contain from about 5% w/w to about 95% w/w of the barium salt.
  • the compositions may be in the form of dispersions, colloids or suspensoids, however, we prefer to use colloids as the preferred embodiment.
  • contrast agents used in the invention may be formulated for administration using physiologically acceptable carriers or excipients in a manner within the skill of the art.
  • the compounds with the addition of pharmaceutically acceptable aids (such as surfactants and emulsifiers) and excipients may be suspended or partially dissolved in an aqueous medium resulting in a dispersion, solution or suspension.
  • pharmaceutically acceptable aids such as surfactants and emulsifiers
  • excipients may be suspended or partially dissolved in an aqueous medium resulting in a dispersion, solution or suspension.
  • tne oily contrast agents are preferably made into emulsions.
  • compositions of the present invention utilising contrast agents of types (1) to (8) defined above
  • Oily Vehicle 0.0 - 55 0.1 - 25 7 - 15
  • compositions of the present invention utilising contrast agents of type (9) defined above comprise the following pharmaceutically acceptable components based on % w/v: Ingredients Broad Range Preferred Range
  • Viscosity modifying 0.001 - 4 0.05 - 1 excipients (% w/v)
  • compositions of the present invention utilising barium salts comprise the following pharmaceutically acceptable components based on % w/v:
  • the concentration of the x-ray contrast agent should be in the range of from 0.01 to 40 mg I/ml, more preferably of from 0.25 to 25 mg I/ml and most
  • the preferred cellulose derivative utilized in the present invention is AVICEL ® RC-591, which is a mixture of about 89 parts microcrystalline cellulose and about 11 parts of sodium carboxymethylcellulose.
  • the x-ray contrast agent present in concentrations lower than the above-stated minimum in formulations does not provide good quality x-ray or CT images, while concentrations above the maximum concentration render the GI tract too radiopaque and do not allow sufficient delineation of the GI tract.
  • Oily materials the density of which approximate the density of the aqueous phase impart stability to emulsions. For that reason low density oils, such as mineral oils, are desirable in preparing the emulsions.
  • low density oils such as mineral oils
  • the x-ray contrast agents are oily substances at room temperature, the presence of an additional oily vehicle is not always necessary. Above about 55% w/v of oil the emulsion is no longer an oil-in-water emulsion but shifts to a water-in-oil emulsion.
  • compositions without the presence of surfactants still provide excellent x-ray images, however, without surfactants the compositions are very difficult to emulsify and only suspensions/dispersions are produced which are less desirable for coating the GI tract and are also less stable on shelf-life. For reason of toxicity it is desirable to keep the concentration of certain surfactants as low as possible; above about 20% w/v the risk of toxicity rapidly increases .
  • the addition of a cellulose derivative to the formulations greatly increases the quality of the x-ray images. At the low extreme of the concentration range there is little or no benefit gained, while above the higher extreme of the concentration range the emulsion is too viscous for administration.
  • viscosity modifying agents may not be necessary; at higher levels than about 15% w/v the viscosity is too high and gels will tend to form.
  • Polysorbate 80 (Tween 80) 5.00
  • Polysorbate 80 (Tween 80) 3.00
  • Polysorbate 80 (Tween 80) 5.00
  • Polysorbate 80 (Tween 80) 5.00
  • polyethylene glycol-400 17.50 Light Mineral Oil, NF 12.50 Polysorbate 80 (Tween 80) 3.37 Sorbitan Mono-oleate (Span 80) 1.64 AVICEL ® RC-591 0.50 q.s. with water to 100% by volume
  • Polysorbate 80 (Tween 80) 5.00 AVICEL ® RC-591 6.50 q.s. with water to 100% by volume
  • Polysorbate 80 (Tween 80) 2.00
  • Polysorbate 80 (Tween 80) 5.00
  • Polysorbate 80 (Tween 80) 3.00
  • Components Amounts in% w/v
  • Polysorbate 80 (Tween 80) 5.00
  • Polysorbate 80 (Tween 80) 5.00
  • Polysorbate 80 (Tween 80) 5.00
  • surfactants or emulsifiers can reduce the interfacial tension between two immiscible phases, i.e., oil-in-aqueous medium. These agents can be used alone or in
  • polydimethylsiloxane simethicone and silica aerogel, 14% w/v stearate emulsifiers and 0.075% w/v sorbic acid, the balance being water, may be used by itself.
  • Intralipid which is an emulsion of fatty acids needs the presence of a suspending agent for it to form an acceptable emulsion with contrast agents of the present invention.
  • the surface active agents may be cationic, anionic, nonionic, zwitterionic or a mixture of two or more of these agents.
  • Suitable cationic surfactants include cetyl
  • Suitable anionic agents include sodium lauryl sulphate, sodium heptadecyl sulphate, alkyl benzenesulphonic acids and salts
  • Zwitterionic surface active agents are substances that when dissolved in water they behave as diprotic acids and, as they ionize, they behave both as a weak base and a weak acid. Since the two charges on the molecule balance each other out the molecules act as neutral molecules.
  • the pH at which the zwitterion concentration is maximum is known as the isoelectric point.
  • Compounds, such as certain amino acids having an isoelectric point at the desired pH of the formulations of the present invention are useful in practicing the present invention.
  • nonionic emulsifiers or surface active agents which, similarly to the nonionic contrast agents, possess a superior toxicological profile to that of anionic, cationic or zwitterionic agents.
  • nonionic emulsifying agents the nonionic emulsifying agents
  • hydrophilic and hydrophobic groups are about evenly balanced. They differ from anionic and cationic surfactants by the absence of charge on the molecule and, for that reason, are generally less of an irritant than the cationic or anionic surfactants.
  • Nonionic surfactants include carboxylic esters,
  • carboxylic ester nonionic surface active agents are the partial, for example monoesters formed by the reaction of fatty and resin acids, for example of about 8 to about 18 carbon atoms, with polyhydric alcohols, for example glycerol, glycols such as mono-, di-, tetra- and hexaethylene glycol, sorbitan, and the like; and similar compounds formed by the direct addition of varying molar ratios of ethylene oxide to the hydroxy group of fatty acids.
  • condensation products of fatty and resin partial acids for example mono-, esters ethylene oxide, such as fatty or resin acid esters of polyoxyethylene sorbitan and sorbitol, for example polyoxyethylene sorbitan, monotall oil esters.
  • fatty and resin partial acids for example mono-, esters ethylene oxide, such as fatty or resin acid esters of polyoxyethylene sorbitan and sorbitol, for example polyoxyethylene sorbitan, monotall oil esters.
  • These may contain, for example, from about 3 to about 80 oxyethylene units per molecule and fatty or resin acid groups of from about 8 to about 18 carbon atoms.
  • Naturally occurring fatty acid mixtures which may be used are those from coconut oil and tallow while examples of single fatty acids are dodecanoic acid and oleic acid.
  • Carboxylic amide nonionic surface active agents are the ammonia, monoethylamine and diethylamine amides of fatty acids having an acyl chain of from about 8 to about 18 carbon atoms.
  • the ethoxylated alkylphenol nonionic surface active agents include various polyethylene oxide condensates of alkylphenols, especially the condensation products of monoalkylphenols or dialkylphenols wherein the alkyl group contains about 6 to about 12 carbon atoms in either branched chain or particularly straight chain configuration, for example, octyl cresol, octyl phenol or nonyl phenol, with ethylene oxide, said ethylene oxide being present in amounts equal to from about 5 to about 25 moles of ethylene oxide per mole of
  • Ethoxylated aliphatic alcohol nonionic surface active agents include the condensation products of aliphatic alcohols having from about 8 to 18 carbon atoms in either straight chain or branched chain configuration, for example oleyl or cetyl alcohol, with ethylene oxide, said ethylene oxide being present in equal amounts from about 30 to about 60 moles of ethylene oxide per mole of alcohol.
  • Preferred nonionic surface active agents include:
  • Sorbitan esters (sold under the trade name Span) having the formula:
  • Polyoxyethylene alkyl ethers having the formula: CH 3 ( CH 2 ) x (O- CH 2 -CH 2 ) y OH where (x + 1) is the number of carbon atoms in the alkyl chain, typically:
  • y is the number of ethylene oxide groups in the hydrophilic chain, typically 10-60.
  • Polyethylene sorbitan fatty acid esters sold under the trade names of Polysorbates 20, 40, 60, 65, 80 & 85, having the formulae (1) and (2)
  • Polyethylene stearates such as:
  • the dosages of the contrast agent used according to the method of the present invention will vary according to the precise nature of the contrast agent used.
  • the dosage should be kept as low as is consistent with achieving contrast enhanced imaging.
  • toxicity potential is minimized.
  • dosages will be in the range of from about 0.1 to about 16.0 g iodine/kg body weight, preferably in the range of from about 0.5 to about 6.0 g iodine/kg of body weight, and most preferably, in the range of from about 1.2 to about 2.0 g iodine/kg body weight for regular x-ray visualization of the GI tract.
  • the contrast agents of the present invention will be in the range of from about 1 to about 600 mg iodine/kg body weight,
  • the concentration of the contrast agent should be in the range of from about 0.001% w/v to about 75% w/v of the formulation, preferably from about 0.05% w/v to about 50% w/v and most preferably of from about 0.1 % w/v to about 20% w/v.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ces compositions de contraste radiologique destinées à l'examen oral ou rétrograde du tractus gastro-intestinal comprennent un agent producteur de contraste radiologique dans un véhicule pharmacologiquement acceptable comportant un dérivé de la cellulose.
PCT/GB1995/000386 1994-02-25 1995-02-24 Compositions de contraste radiologique contenant des derives de la cellulose WO1995022995A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX9603611A MX9603611A (es) 1994-02-25 1995-02-24 Composiciones de contraste para rayos x, que contienen derivados de celulosa.
CN95192256A CN1146159A (zh) 1994-02-25 1995-02-24 含有纤维素衍生物的x-射线造影组合物
AU18163/95A AU1816395A (en) 1994-02-25 1995-02-24 X-ray contrast compositions containing cellulose derivatives
JP7522205A JPH09509424A (ja) 1994-02-25 1995-02-24 セルロース誘導体を含むｘ線造影組成物
EP95909853A EP0746339A1 (fr) 1994-02-25 1995-02-24 Compositions de contraste radiologique contenant des derives de la cellulose
FI963299A FI963299A0 (fi) 1994-02-25 1996-08-23 Röntgenvarjoainekoostumukset, jotka sisältävät selluloosajohdannaisia

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US229,048 1981-01-28
US08/201,731 US5422114A (en) 1993-03-01 1994-02-25 Compositions of iodoaniline derivatives and cellulose derivatives for visualization of the gastrointestinal tract
US08/206,552 US5443814A (en) 1992-05-01 1994-03-04 X-ray contrast compositions containing iodophenoxyalkanes and cellulose derivatives
US08/217,138 US5385721A (en) 1993-02-04 1994-03-22 Compositions of alkylbenzenes and cellulose derivatives for visualization of the gastrointestinal tract
US07/216,988 US5385720A (en) 1993-03-11 1994-03-23 Compositions of iodobenzoic acid derivatives and cellulose derivatives for visualization of the gastrointestinal tract
US08/222,787 US5466435A (en) 1993-03-11 1994-04-04 Compositions of iodophenoxy alkylene ethers and cellulose derivatives for visualization of the gastrointestinal tract
US08/227,423 US5368837A (en) 1994-04-14 1994-04-14 X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US08/227,422 US5543132A (en) 1994-04-14 1994-04-14 X-ray contrast compositions containing a barium salt and a cellulose derivative
US08/227,415 US5525327A (en) 1994-04-14 1994-04-14 Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US08/229,048 US5385722A (en) 1993-03-31 1994-04-18 Compositions of iodophenyl esters and iodophenyl sulfonates and cellulose derivatives for visualization of the gastrointestinal tract
US08/246,888 US5607660A (en) 1993-02-02 1994-05-20 Compositions of iodophenoxy alkanes and iodophenyl ethers in combination with cellulose derivatives for visualization of the gastrointestinal tract
US227,415 1994-05-20
US246,888 1994-05-20
US227,422 1994-05-20
US206,552 1994-05-20
US217,138 1994-05-20
US222,787 1994-05-20
US201,731 1994-05-20
US227,423 1994-05-20
US216,988 1994-05-20

Publications (1)

Publication Number Publication Date
WO1995022995A1 true WO1995022995A1 (fr) 1995-08-31

Family

ID=27581136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/000386 WO1995022995A1 (fr) 1994-02-25 1995-02-24 Compositions de contraste radiologique contenant des derives de la cellulose

Country Status (10)

Country Link
EP (1) EP0746339A1 (fr)
JP (1) JPH09509424A (fr)
CN (1) CN1146159A (fr)
AU (1) AU1816395A (fr)
CA (1) CA2184089A1 (fr)
FI (1) FI963299A0 (fr)
HU (1) HUT76336A (fr)
MX (1) MX9603611A (fr)
NO (1) NO963540L (fr)
WO (1) WO1995022995A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030736A3 (fr) * 1996-02-20 1997-12-18 Nycomed Imaging As Milieu de contraste
WO2009097277A1 (fr) * 2008-02-01 2009-08-06 Trustees Of Boston University Agents de contraste cationiques et leurs méthodes d'utilisation
US7684852B2 (en) 2002-04-06 2010-03-23 Bracco Diagnostics Inc. System, formulation, kit and method for tagging colonic residue in an individual
WO2015024025A1 (fr) 2013-08-16 2015-02-19 The Regents Of The University Of California Produit de contraste à base de silicium pour administration par voie entérale pour examen par scanner
WO2017165841A1 (fr) * 2016-03-25 2017-09-28 Nanoprobes, Inc. Particules à base d'iode
US11033640B2 (en) 2013-03-15 2021-06-15 The Regents Of The University Of California Enteric CT contrast material based on low-z atoms

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109540936A (zh) * 2019-01-11 2019-03-29 大连大学附属中山医院 一种用于高分辨率ct及x线动脉、静脉或管道的室温造影剂及其制备方法
US20220204655A1 (en) * 2020-12-28 2022-06-30 Boston Scientific Scimed, Inc. Polysaccharides having improved radiocontrast properties

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
CH338274A (fr) * 1954-01-08 1959-05-15 Schering Corp Utilisation comme agents radio-opaques de phénoxy-acides gras polyiodés
FR2085692A1 (fr) * 1970-03-10 1971-12-31 Squibb & Sons Inc
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
EP0568156A1 (fr) * 1992-05-01 1993-11-03 Nycomed Imaging As Formulations de contraste aux raxons X et leurs utilisations dans la visualisation du tractus gastro-intestinal
EP0568155A1 (fr) * 1992-05-01 1993-11-03 Nycomed Imaging As Formulations de contrast aux raxons X contenant des substances filmogènes
WO1994005336A1 (fr) * 1992-09-01 1994-03-17 Sterling Wintrop Inc. Compositions de contraste radiographiques filmogenes
US5308607A (en) * 1993-02-04 1994-05-03 Sterling Winthrop Inc. Compositions of alkylbenzenes for visualization of the gastrointestinal tract using X-ray contrast
US5310537A (en) * 1993-03-01 1994-05-10 Sterling Winthrop Inc. Compositions of iodoaniline derivatives for visualization of the gastrointestinal tract
US5310538A (en) * 1993-03-11 1994-05-10 Sterling Winthrop Inc. Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract
US5312616A (en) * 1993-03-11 1994-05-17 Sterling Winthrop Inc. Compositions of iodobenzoic acid derivatives in film-forming materials for visualization of the gastrointestinal tract
US5316755A (en) * 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
US5318769A (en) * 1993-03-31 1994-06-07 Sterling Winthrop Inc. Compositions of iodophenyl esters for X-ray visualization of the gastrointestinal tract
EP0603922A1 (fr) * 1992-12-16 1994-06-29 NanoSystems L.L.C. Dérivés iodés d'aroyloxy esters et leur application à titre d'agent de contraste aux rayons X
EP0603923A1 (fr) * 1992-12-14 1994-06-29 NanoSystems L.L.C. Dérivés d'acides aromatiques iodés et leur application à titre d'agent de contraste aux rayons X
US5326553A (en) * 1993-02-02 1994-07-05 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualization of the gastrointestinal tract
US5330740A (en) * 1993-03-01 1994-07-19 Sterling Winthrop Inc. Compositions of iodoaniline derivatives in film-forming materials for visualization of the gastrointestinal tract
US5336484A (en) * 1993-03-31 1994-08-09 Sterling Winthrop Inc. Compositions of iodophenyl esters and iodophenyl sulfonates in film-forming materials for visualization of the gastronintestinal tract
EP0609589A2 (fr) * 1993-02-04 1994-08-10 Nycomed Imaging As Composition à base de bensénes alkyles dans des matériaux formateur de film pour la visualisation du tract gastrointestinal
US5342605A (en) * 1992-05-01 1994-08-30 Sterling Winthrop Inc. Polymeric X-ray compositions containing iodinated polymeric beads
EP0614668A2 (fr) * 1993-03-11 1994-09-14 Nycomed Imaging As Composition des dérivés d'acide iodobenzoique pour la visualisation du tractus gastrointestinal

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
CH338274A (fr) * 1954-01-08 1959-05-15 Schering Corp Utilisation comme agents radio-opaques de phénoxy-acides gras polyiodés
FR2085692A1 (fr) * 1970-03-10 1971-12-31 Squibb & Sons Inc
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
EP0568156A1 (fr) * 1992-05-01 1993-11-03 Nycomed Imaging As Formulations de contraste aux raxons X et leurs utilisations dans la visualisation du tractus gastro-intestinal
EP0568155A1 (fr) * 1992-05-01 1993-11-03 Nycomed Imaging As Formulations de contrast aux raxons X contenant des substances filmogènes
US5342605A (en) * 1992-05-01 1994-08-30 Sterling Winthrop Inc. Polymeric X-ray compositions containing iodinated polymeric beads
WO1994005336A1 (fr) * 1992-09-01 1994-03-17 Sterling Wintrop Inc. Compositions de contraste radiographiques filmogenes
EP0603923A1 (fr) * 1992-12-14 1994-06-29 NanoSystems L.L.C. Dérivés d'acides aromatiques iodés et leur application à titre d'agent de contraste aux rayons X
EP0603922A1 (fr) * 1992-12-16 1994-06-29 NanoSystems L.L.C. Dérivés iodés d'aroyloxy esters et leur application à titre d'agent de contraste aux rayons X
EP0609587A2 (fr) * 1993-02-02 1994-08-10 Nycomed Imaging As Compositions à base de iodophenoxyalcanes et iodophényléthers dans des matériaux formateurs de film pour la visualisation du tract gastrointestinal
US5316755A (en) * 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
US5326553A (en) * 1993-02-02 1994-07-05 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualization of the gastrointestinal tract
US5308607A (en) * 1993-02-04 1994-05-03 Sterling Winthrop Inc. Compositions of alkylbenzenes for visualization of the gastrointestinal tract using X-ray contrast
EP0609589A2 (fr) * 1993-02-04 1994-08-10 Nycomed Imaging As Composition à base de bensénes alkyles dans des matériaux formateur de film pour la visualisation du tract gastrointestinal
US5310537A (en) * 1993-03-01 1994-05-10 Sterling Winthrop Inc. Compositions of iodoaniline derivatives for visualization of the gastrointestinal tract
US5330740A (en) * 1993-03-01 1994-07-19 Sterling Winthrop Inc. Compositions of iodoaniline derivatives in film-forming materials for visualization of the gastrointestinal tract
US5310538A (en) * 1993-03-11 1994-05-10 Sterling Winthrop Inc. Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract
US5312616A (en) * 1993-03-11 1994-05-17 Sterling Winthrop Inc. Compositions of iodobenzoic acid derivatives in film-forming materials for visualization of the gastrointestinal tract
EP0614668A2 (fr) * 1993-03-11 1994-09-14 Nycomed Imaging As Composition des dérivés d'acide iodobenzoique pour la visualisation du tractus gastrointestinal
EP0614669A2 (fr) * 1993-03-11 1994-09-14 Nycomed Imaging As Compositions des dérivés d'acide iodobenzoique contenant des substances filmogènes pour la visualisation du tractus gastrointestinal
EP0614670A2 (fr) * 1993-03-11 1994-09-14 Nycomed Imaging As Compositions d'éthers d'alkylène iodophénoxy contenant des substances filmogènes pour la visualisation du tractus gastrointestinal
US5336484A (en) * 1993-03-31 1994-08-09 Sterling Winthrop Inc. Compositions of iodophenyl esters and iodophenyl sulfonates in film-forming materials for visualization of the gastronintestinal tract
US5318769A (en) * 1993-03-31 1994-06-07 Sterling Winthrop Inc. Compositions of iodophenyl esters for X-ray visualization of the gastrointestinal tract
EP0617970A2 (fr) * 1993-03-31 1994-10-05 Nycomed Imaging As Composition d'ester et sulfonates de iodophényl dans des matières filmogènes pour l'imagerie du tract gastro-intestinal

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030736A3 (fr) * 1996-02-20 1997-12-18 Nycomed Imaging As Milieu de contraste
US7684852B2 (en) 2002-04-06 2010-03-23 Bracco Diagnostics Inc. System, formulation, kit and method for tagging colonic residue in an individual
WO2009097277A1 (fr) * 2008-02-01 2009-08-06 Trustees Of Boston University Agents de contraste cationiques et leurs méthodes d'utilisation
EP2247314A1 (fr) * 2008-02-01 2010-11-10 Trustees of Boston University Agents de contraste cationiques et leurs méthodes d'utilisation
EP2247314A4 (fr) * 2008-02-01 2013-11-27 Univ Boston Agents de contraste cationiques et leurs méthodes d'utilisation
US11033640B2 (en) 2013-03-15 2021-06-15 The Regents Of The University Of California Enteric CT contrast material based on low-z atoms
WO2015024025A1 (fr) 2013-08-16 2015-02-19 The Regents Of The University Of California Produit de contraste à base de silicium pour administration par voie entérale pour examen par scanner
EP3033012A4 (fr) * 2013-08-16 2017-04-19 The Regents of the University of California Produit de contraste à base de silicium pour administration par voie entérale pour examen par scanner
WO2017165841A1 (fr) * 2016-03-25 2017-09-28 Nanoprobes, Inc. Particules à base d'iode

Also Published As

Publication number Publication date
MX9603611A (es) 1997-04-30
CA2184089A1 (fr) 1995-08-31
AU1816395A (en) 1995-09-11
EP0746339A1 (fr) 1996-12-11
FI963299L (fi) 1996-08-23
CN1146159A (zh) 1997-03-26
NO963540D0 (no) 1996-08-23
HU9602321D0 (en) 1996-10-28
JPH09509424A (ja) 1997-09-22
HUT76336A (en) 1997-08-28
NO963540L (no) 1996-10-23
FI963299A0 (fi) 1996-08-23

Similar Documents

Publication Publication Date Title
US5368837A (en) X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US5318768A (en) Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent
US5360604A (en) X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combination with pharmaceutically acceptable clays
US5342605A (en) Polymeric X-ray compositions containing iodinated polymeric beads
US5352434A (en) X-ray contrast compositions containing a barium salt and film-forming materials
US5310538A (en) Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract
US5525327A (en) Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US5422114A (en) Compositions of iodoaniline derivatives and cellulose derivatives for visualization of the gastrointestinal tract
US5385722A (en) Compositions of iodophenyl esters and iodophenyl sulfonates and cellulose derivatives for visualization of the gastrointestinal tract
WO1995028969A1 (fr) Compositions de contraste radiologique contenant des argiles acceptables sur le plan pharmacologique
WO1995022995A1 (fr) Compositions de contraste radiologique contenant des derives de la cellulose
US5385721A (en) Compositions of alkylbenzenes and cellulose derivatives for visualization of the gastrointestinal tract
EP0568155A1 (fr) Formulations de contrast aux raxons X contenant des substances filmogènes
US5310537A (en) Compositions of iodoaniline derivatives for visualization of the gastrointestinal tract
US5385720A (en) Compositions of iodobenzoic acid derivatives and cellulose derivatives for visualization of the gastrointestinal tract
US5443814A (en) X-ray contrast compositions containing iodophenoxyalkanes and cellulose derivatives
US5405600A (en) X-ray contrast compositions containing film-forming materials
US5466435A (en) Compositions of iodophenoxy alkylene ethers and cellulose derivatives for visualization of the gastrointestinal tract
US5492687A (en) Compositions of iodophenoxy alkylene ethers and pharmaceutically acceptable clays for visualization of the gastrointestinal tract
EP0617970A2 (fr) Composition d'ester et sulfonates de iodophényl dans des matières filmogènes pour l'imagerie du tract gastro-intestinal
US5543132A (en) X-ray contrast compositions containing a barium salt and a cellulose derivative
US5424056A (en) X-ray contrast compositions containing iodoaniline derivatives and pharmaceutically acceptable clays
WO1994005336A1 (fr) Compositions de contraste radiographiques filmogenes
US5484585A (en) Compositions of iodobenzoic acid derivatives and pharmaceutically acceptable clays for visualization of the gastrointestinal tract
US5472682A (en) Compositions of iodophenyl esters and iodophenyl sulfonates and pharmaceutically acceptable clays for visualization of the gastrointestinal tract

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95192256.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995909853

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2184089

Country of ref document: CA

Ref document number: 963299

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1995909853

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995909853

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载